Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation

被引:0
作者
Inken Hilgendorf
Daniel Wolff
Christian Junghanss
Christoph Kahl
Malte Leithaeuser
Beate Steiner
Jochen Casper
Mathias Freund
机构
[1] University of Rostock,Department of Internal Medicine, Division of Haematology and Oncology
[2] Südstadtklinikum,Department of Internal Medicine, Division of Haematology and Oncology
来源
Annals of Hematology | 2008年 / 87卷
关键词
Central nervous system relapse; Haematopoietic stem cell transplantation; Liposomal cytarabine;
D O I
暂无
中图分类号
学科分类号
摘要
Liposomal cytarabine has been proven to be useful for the prevention and intrathecal treatment of neoplastic meningitis. It has no demonstrable myelosuppressive effects and may therefore be an attractive alternative for prophylaxis and treatment of the central nervous system (CNS) relapse after allogeneic haematopoietic stem cell transplantation (HSCT). The use of liposomal cytarabine had not been reported in HSCT recipients. We retrospectively reviewed the feasibility of liposomal cytarabine in the prophylaxis (n = 2) and treatment (n = 4) of neoplastic meningitis in a cohort of patients after allogeneic HSCT. This report focusses on neurological complications after intrathecal application of liposomal cytarabine. Mild headache was the most commonly reported adverse event. Two patients experienced sacral radiculopathy with irreversible cauda equina syndrome in one patient. Another patient progressed with pre-existing leukencephalopathy. Intrathecal liposomal cytarabine should be used very cautiously in allogeneic HSCT recipients with a history of CNS complications potentially involving cerebral-spinal fluid circulation, since significant neurotoxicity was observed in patients with extensive CNS-directed pre-treatment. The feasibility and safety of liposomal cytarabine in HSCT recipients has to be evaluated in a prospective study.
引用
收藏
页码:1009 / 1012
页数:3
相关论文
共 43 条
[1]  
Sancho JM(2006)Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases Haematologica 91 ECR02-3116
[2]  
Ribera JM(1999)Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis J Clin Oncol 17 3110-2193
[3]  
Romero MJ(1993)Extended CSF cytarabine exposure following intrathecal administration of DTC 101 J Clin Oncol 11 2186-1851
[4]  
Martin-Reina V(2007)Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphoma Leuk Lymphoma 48 1849-199
[5]  
Giraldo P(1986)The risks of central nervous system relapse and leukencephalopathy in patients receiving marrow transplants for acute leukaemia Blood 67 195-917
[6]  
Ruiz E(1989)Central nervous system relapses after bone marrow Transplantation for acute leukaemia in remission Cancer 64 1796-3218
[7]  
Glantz MJ(1995)Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases Arch Neurol 52 912-undefined
[8]  
LaFollette S(2007)Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia Blood 109 3214-undefined
[9]  
Jaeckle KA(undefined)undefined undefined undefined undefined-undefined
[10]  
Shapiro W(undefined)undefined undefined undefined undefined-undefined